- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pelthos Therapeutics Inc (PTHS)
Pelthos Therapeutics Inc stock price live, this page displays NYSE PTHS stock exchange data. View the PTHS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pelthos Therapeutics Inc real time stock price chart below.
What Is the Pelthos Therapeutics Inc Stock Price Today?
The Pelthos Therapeutics Inc stock price today is 27.315.
What Is the Stock Symbol for Pelthos Therapeutics Inc?
The stock symbol for Pelthos Therapeutics Inc is "PTHS."
What Stock Exchange Does Pelthos Therapeutics Inc Trade On?
Pelthos Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Pelthos Therapeutics Inc a Good Stock to Buy?
Determining whether Pelthos Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTHS quote. (ISIN: US1711262048)
What Is the Pelthos Therapeutics Inc Stock Price Today?
The Pelthos Therapeutics Inc stock price today is 27.315.
What Is the Stock Symbol for Pelthos Therapeutics Inc?
The stock symbol for Pelthos Therapeutics Inc is "PTHS."
What Stock Exchange Does Pelthos Therapeutics Inc Trade On?
Pelthos Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Pelthos Therapeutics Inc a Good Stock to Buy?
Determining whether Pelthos Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTHS quote. (ISIN: US1711262048)
27.315
+1.495(+5.79%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.920
27.315
52 wk Range
18.190
37.500
PTHS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.92027.315
52 wk Range
18.19037.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PTHS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
53.143
Upside
+94.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Form 4 Pelthos Therapeutics Inc For: 7 July- Investing.com
Form 8K Pelthos Therapeutics Inc For: 13 August- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 53.143
(+94.56% Upside)
Pelthos Therapeutics Inc Earnings Call Summary for Q2/2026
- ZELSUVMI revenue surged 45% quarter-over-quarter to $15.4M with prescription units up 48% to 11,925, driving strong commercial momentum.
- EPS missed sharply at -$6.62 vs. forecast -$0.51, reflecting elevated launch costs; net loss totaled $23.4M despite improving adjusted EBITDA.
- Stock declined 2.11% to $28.30 as investors weighed robust sales growth against wider-than-expected losses and cash position of $24.2M.
- Management expects ZELSUVMI demand to continue despite seasonal Q3 slowdown; XEPI launch delayed to March 2027, XEGLYZE targeted for Q3 2027.
- Gross-to-net rate of 29.6% expected to rise to low-to-mid 30% range; future product launches to leverage existing sales infrastructure.
Last Updated: 08/13/2026, 09:44 PM
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-6.62 / -0.51
Revenue / Forecast
15.6M / --
Compare PTHS to Peers and Sector
Metrics to compare | PTHS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTHSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.1x | −3.7x | −0.3x | |
PEG Ratio | 0.01 | −0.04 | 0.00 | |
Price/Book | −62.4x | 2.1x | 2.6x | |
Price / LTM Sales | 2.2x | 73.4x | 3.1x | |
Upside (Analyst Target) | 93.6% | 155.7% | 48.5% | |
Fair Value Upside | Unlock | 6.2% | 6.3% | Unlock |
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pelthos Therapeutics (PTHS) Stock Price Today?
The Pelthos Therapeutics stock price today is 27.315 USD.
What Stock Exchange Does Pelthos Therapeutics Trade On?
Pelthos Therapeutics is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Pelthos Therapeutics?
The stock symbol for Pelthos Therapeutics is "PTHS."
What Is the Pelthos Therapeutics Market Cap?
As of today, Pelthos Therapeutics market cap is 89.740M USD.
What Is Pelthos Therapeutics's Earnings Per Share (TTM)?
The Pelthos Therapeutics EPS (TTM) is -26.360.
When Is the Next Pelthos Therapeutics Earnings Date?
Pelthos Therapeutics will release its next earnings report on Nov 12, 2026.
From a Technical Analysis Perspective, Is PTHS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Pelthos Therapeutics Stock Split?
Pelthos Therapeutics has split 1 times.
How Many Employees Does Pelthos Therapeutics Have?
Pelthos Therapeutics has 92 employees.
What is the current trading status of Pelthos Therapeutics (PTHS)?
As of Aug 20, 2026, Pelthos Therapeutics (PTHS) is trading at a price of 27.315 USD, with a previous close of 25.820 USD. The stock has fluctuated within a day range of 25.920 USD to 27.315 USD, while its 52-week range spans from 18.190 USD to 37.500 USD.
What Is Pelthos Therapeutics (PTHS) Price Target According to Analysts?
The average 12-month price target for Pelthos Therapeutics is 53.143 USD, with a high estimate of 64 USD and a low estimate of 45 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +94.56% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.